Amicus Therapeutics is a biotechnology company founded in 2002 and headquartered in Philadelphia, Pennsylvania. The company is focused on developing therapies for rare and orphan diseases, particularly lysosomal storage disorders. Amicus has a number of product candidates in various stages of development, including migalastat, a drug for the treatment of Fabry disease, and AT-GAA, a drug for the treatment of Pompe disease. The company has partnerships with a number of other biotechnology and pharmaceutical companies, including GlaxoSmithKline and JCR Pharmaceuticals.